Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PolyNovo (PNV) has signed deal with group purchasing organisation Premier for the supply of NovoSorb BTM
  • NovoSorb BTM is a dermal scaffold that helps regenerate skin lost through extensive surgery or burns
  • The agreement between PolyNovo and Premier allows member hospitals access to BTM at special pricing and terms negotiated with PolyNovo
  • PolyNovo’s sales team will now be able to enter hospitals that were previously restricted and will have a streamlined procurement process to facilitate faster NovoSorb BTM adoption
  • PolyNovo shares are up 2.79 per cent, trading at $2.95

PolyNovo (PNV) has signed deal with group purchasing organisation Premier for the supply of NovoSorb BTM.

NovoSorb BTM is a dermal scaffold that helps regenerate skin lost through extensive surgery or burns.

The agreement between PolyNovo and the group purchasing organisation (GPO) allows Premier member hospitals access to BTM at the special pricing and terms negotiated with PolyNovo.

The program ensures that its member hospitals have timely access to products that can drive high-quality, cost-effective care.

Premier currently services around 4100 health facilities and hospital members, including over 2000 acute care hospitals with 100 trauma centres and 63 children’s hospitals.

From April 1, PolyNovo will have access to these hospitals and Premier’s regional representatives, responsible for introducing new technology to members to improve utilisation and care efficiencies.

PolyNovo’s marketing team and consultants will be providing the Premier team with training, materials and support to enable them to facilitate the uptake of NovoSorb BTM amongst their members.

“This signing with Premier, the second largest GPO in the U.S., is a major milestone,” said Managing Director of PolyNovo, Paul Brennan.

“These GPO agreements put our disruptive BTM on a much larger list of hospitals than our sales team can get around in the short term. We will continue expanding our sales team into new markets to support hospitals and surgeons but now also to match the geographical footprint of the GPOs”.

PolyNovo shares are up 2.79 per cent, trading at $2.95 at 2:55 pm AEDT.  

PNV by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.